{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:12:52Z","timestamp":1791666772017,"version":"4.3.4"},"reference-count":52,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Fabry disease (FD) is an X-linked genetic disease caused by deficient \u03b1 galactosidase A activity, leading to a lysosomal storage disorder of globotriaosylceramide, causing organ damages. There are two most common clinical manifestations of the disease: classic FD with a typical onset of symptoms in childhood in males, and later-onset variants which may include female heterozygotes. The highly heterogeneous and nonspecific nature of FD\u2019s symptoms and limited physicians\u2019 awareness result in a significant diagnostic and therapeutic delay. Even though the implementation of newborn screening (NBS) gives us an opportunity for early diagnosis and timely treatment, it has not yet been universally adopted. Over twenty pilot studies and screening programs worldwide have been published, showing that FD is more prevalent than previously estimated, exceeding 1 in 40,000 males, mainly due to the high incidence of variants of unknown significance (VUSs). They also raised controversies regarding the diagnostic methods, results interpretation, ethical issues, clinical approach, and economic burden. This review analyzes recent studies of NBS for FD; examines the screening methods, prevalence findings, and natural history data; and assesses the benefits and risks of NBS. We conclude with suggestions for the screening program design and research priorities to ensure that screening leads to improved health outcomes with acceptable costs and psychosocial impact.<\/jats:p>","DOI":"10.3390\/ijms262412125","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:43:46Z","timestamp":1765964626000},"page":"12125","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Newborn Screening in Fabry Disease"],"prefix":"10.3390","volume":"26","author":[{"given":"Marta","family":"Olszewska","sequence":"first","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Schwermer","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6237-0814","authenticated-orcid":false,"given":"Krzysztof","family":"Pawlaczyk","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Diseases, Poznan University of Medical Sciences, 60-355 Poznan, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry Disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic Defect in Fabry\u2019s Disease: Ceramidetrihexosidase Deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.167.3922.1268","article-title":"Fabry\u2019s Disease: Alpha-Galactosidase Deficiency","volume":"167","author":"Kint","year":"1970","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7364","DOI":"10.1073\/pnas.82.21.7364","article-title":"Fabry Disease: Isolation of a cDNA Clone Encoding Human Alpha-Galactosidase A","volume":"82","author":"Calhoun","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/gim.2014.120","article-title":"Fabry Disease in Infancy and Early Childhood: A Systematic Literature Review","volume":"17","author":"Laney","year":"2015","journal-title":"Genet. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.2174\/13816128113199990352","article-title":"Anderson-Fabry Disease: A Multiorgan Disease","volume":"19","author":"Tuttolomondo","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_7","first-page":"408","article-title":"Neurometabolic Hereditary Diseases of Adults","volume":"51","author":"Hoffmann","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-Chromosome Inactivation in Female Patients with Fabry Disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.clinbiochem.2011.03.141","article-title":"Whole-Blood Alpha-D-Galactosidase A Activity for the Identification of Fabry\u2019s Patients","volume":"44","author":"Massaccesi","year":"2011","journal-title":"Clin. Biochem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry Disease Defined: Baseline Clinical Manifestations of 366 Patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.2147\/DDDT.S313789","article-title":"Prompt Agalsidase Alfa Therapy Initiation Is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis","volume":"15","author":"Hughes","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s12325-024-03041-2","article-title":"Effects of Current Therapies on Disease Progression in Fabry Disease: A Narrative Review for Better Patient Management in Clinical Practice","volume":"42","author":"Mignani","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"International Collaborative Fabry Disease Study Group. Safety and Efficacy of Recombinant Human Alpha-Galactosidase A Replacement Therapy in Fabry\u2019s Disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Sanders, K.A., Gavrilov, D.K., Oglesbee, D., Raymond, K.M., Tortorelli, S., Hopwood, J.J., Lorey, F., Majumdar, R., Kroll, C.A., and McDonald, A.M. (2020). A Comparative Effectiveness Study of Newborn Screening Methods for Four Lysosomal Storage Disorders. Int. J. Neonatal Screen., 6.","DOI":"10.3390\/ijns6020044"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ymgme.2020.04.006","article-title":"A Comprehensive Testing Algorithm for the Diagnosis of Fabry Disease in Males and Females","volume":"130","author":"Stiles","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene Mutations versus Clinically Relevant Phenotypes: Lyso-Gb3 Defines Fabry Disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, Phenotype and Disease Severity Reflected by Serum LysoGb3 Levels in Patients with Fabry Disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Duro, G., Zizzo, C., Cammarata, G., Burlina, A., Burlina, A., Polo, G., Scalia, S., Oliveri, R., Sciarrino, S., and Francofonte, D. (2018). Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123726"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13052-016-0320-1","article-title":"Metabolic Progression to Clinical Phenotype in Classic Fabry Disease","volume":"43","author":"Spada","year":"2017","journal-title":"Ital. J. Pediatr."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Burlina, A.B., Polo, G., Rubert, L., Gueraldi, D., Cazzorla, C., Duro, G., Salviati, L., and Burlina, A.P. (2019). Implementation of Second-Tier Tests in Newborn Screening for Lysosomal Disorders in North Eastern Italy. Int. J. Neonatal Screen., 5.","DOI":"10.3390\/ijns5020024"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"109082","DOI":"10.1016\/j.ymgme.2025.109082","article-title":"Enhancing Fabry Disease Screening and Diagnostic Efficiency: Integration of Enzyme, Biomarker, and next-Generation Sequencing Testing","volume":"145","author":"Pan","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.cca.2011.10.023","article-title":"The Use of High Resolution Melting Analysis to Detect Fabry Mutations in Heterozygous Females via Dry Bloodspots","volume":"413","author":"Tai","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ymgme.2014.02.004","article-title":"High-Throughput Detection of Common Sequence Variations of Fabry Disease in Taiwan Using DNA Mass Spectrometry","volume":"111","author":"Lee","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"117889","DOI":"10.1016\/j.cca.2024.117889","article-title":"Newborn Genetic Screening for Fabry Disease: Insights from a Retrospective Analysis in Nanjing, China","volume":"557","author":"Sun","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ndt\/gfx009","article-title":"Parapelvic Cysts, a Distinguishing Feature of Renal Fabry Disease","volume":"33","author":"Pisani","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Giovannetti, F., D\u2019Andrea, M., Bracci, F., Frustaci, A., Chimenti, C., Mangiantini, P., Lambiase, A., and Marenco, M. (2024). Anderson-Fabry Disease: Focus on Ophthalmological Implications. Life, 14.","DOI":"10.3390\/life14121531"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1007\/s00415-023-11826-8","article-title":"Brain MRI Correlations with Disease Burden and Biomarkers in Fabry Disease","volume":"270","author":"Zhao","year":"2023","journal-title":"J. Neurol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.2174\/13816128113199990387","article-title":"Neurological Complications of Anderson-Fabry Disease","volume":"19","author":"Tuttolomondo","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_31","first-page":"100841","article-title":"Hearing Loss in Fabry Disease: A 16 Year Follow-up Study of the Danish Nationwide Cohort","volume":"31","author":"Yazdanfard","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Gragnaniello, V., Burlina, A.P., Polo, G., Giuliani, A., Salviati, L., Duro, G., Cazzorla, C., Rubert, L., Maines, E., and Germain, D.P. (2021). Newborn Screening for Fabry Disease in Northeastern Italy: Results of Five Years of Experience. Biomolecules, 11.","DOI":"10.3390\/biom11070951"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry Disease: Guidelines for the Evaluation and Management of Multi-Organ System Involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry Disease Revisited: Management and Treatment Recommendations for Adult Patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for Initiation and Cessation of Enzyme Replacement Therapy in Patients with Fabry Disease: The European Fabry Working Group Consensus Document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/cge.13546","article-title":"Consensus Recommendations for Diagnosis, Management and Treatment of Fabry Disease in Paediatric Patients","volume":"96","author":"Germain","year":"2019","journal-title":"Clin. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn Screening for Fabry Disease in Taiwan Reveals a High Incidence of the Later-Onset GLA Mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/jhg.2013.48","article-title":"Newborn Screening for Fabry Disease in Japan: Prevalence and Genotypes of Fabry Disease in a Pilot Study","volume":"58","author":"Inoue","year":"2013","journal-title":"J. Hum. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Gragnaniello, V., Burlina, A.P., Commone, A., Gueraldi, D., Puma, A., Porc\u00f9, E., Stornaiuolo, M., Cazzorla, C., and Burlina, A.B. (2023). Newborn Screening for Fabry Disease: Current Status of Knowledge. Int. J. Neonatal Screen., 9.","DOI":"10.3390\/ijns9020031"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","article-title":"An Expert Consensus on Practical Clinical Recommendations and Guidance for Patients with Classic Fabry Disease","volume":"137","author":"Germain","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","article-title":"Newborn Screening for Lysosomal Storage Disorders in Illinois: The Initial 15-Month Experience","volume":"190","author":"Burton","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e1666","DOI":"10.1002\/mgg3.1666","article-title":"The Benefits and Challenges of Family Genetic Testing in Rare Genetic Diseases-Lessons from Fabry Disease","volume":"9","author":"Germain","year":"2021","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10897-007-9128-x","article-title":"Diagnosis of Fabry Disease via Analysis of Family History","volume":"17","author":"Laney","year":"2008","journal-title":"J. Genet. Couns."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/jmg-2022-108523","article-title":"Prevalence of Fabry Disease-Causing Variants in the UK Biobank","volume":"60","author":"Gilchrist","year":"2023","journal-title":"J. Med. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1542\/pir.30.5.193","article-title":"The Vulnerable Child Syndrome","volume":"30","author":"Kokotos","year":"2009","journal-title":"Pediatr. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1177\/0022146510386794","article-title":"Patients-in-Waiting: Living between Sickness and Health in the Genomics Era","volume":"51","author":"Timmermans","year":"2010","journal-title":"J. Health Soc. Behav."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.12669\/pjms.334.12975","article-title":"Ethical Issues in Managing Lysosomal Storage Disorders in Children in Low and Middle Income Countries","volume":"33","author":"Afroze","year":"2017","journal-title":"Pak. J. Med. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e70104","DOI":"10.1002\/jgc4.70104","article-title":"Perspectives on Newborn Screening for Fabry Disease Based on Mothers\u2019 Experiences in Japan","volume":"34","author":"Sasaki","year":"2025","journal-title":"J. Genet. Couns."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ymgme.2013.03.008","article-title":"Fabry Patients\u2019 Experiences with the Timing of Diagnosis Relevant for the Discussion on Newborn Screening","volume":"109","author":"Bouwman","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ymgme.2016.07.009","article-title":"Patients\u2019 Perspectives on Newborn Screening for Later-Onset Lysosomal Storage Diseases","volume":"119","author":"Lisi","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/jgc4.1421","article-title":"Opinions of Adults Affected with Later-Onset Lysosomal Storage Diseases Regarding Newborn Screening: A Qualitative Study","volume":"30","author":"Lisi","year":"2021","journal-title":"J. Genet. Couns."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12125\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:44:54Z","timestamp":1765964694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":52,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262412125"],"URL":"https:\/\/doi.org\/10.3390\/ijms262412125","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}